title: Stability and CTL-activity of P40/ELA melanoma vaccine candidate.
abstract: The decapeptide ELA (ELAGIGILTV), a Melan-A/MART-1 antigen immunodominant peptide analogue, is an interesting melanoma vaccine candidate alone or in combination with other tumour antigens. P40, the recombinant outer membrane protein A of Klebsiella pneumoniae (kpOmpA), was recently shown to target dendritic cells and to induce peptide-specific CTLs. Here we investigated the adjuvant role of P40 mixed or chemically conjugated to ELA. This compound is an N-terminal glutamic acid-containing peptide. However, it has been reported that the amino group and the gamma-carboxylic group of glutamic acids easily condense to form pyroglutamic derivatives. Usually, to overcome this stability problem, peptides of pharmaceutical interest were developed with a pyroglutamic acid instead of N-terminal glutamic acid, without loss of pharmacological properties. Unfortunately, the pyroglutamic acid derivative (PyrELA) as well as the N-terminal acetyl capped derivative (AcELA) failed to elicit CTL activity when mixed with P40 adjuvant protein. Despite the apparent minor modifications introduced by PyrELA and AcELA, these two derivatives have probably lower affinity than ELA for the class I Major Histocompatibility Complex. Furthermore, this stability problem is worse in the case of clinical grade ELA, produced as an acetate salt, like most of the pharmaceutical grade peptides. We report here that the hydrochloride shows a higher stability than the acetate and may be suitable for use in man.
authors.affiliation: Centre d'Immunologie Pierre Fabre (CIPF), bioMérieux-Pierre Fabre, 5 Avenue Napoléon III, F-74164 Saint-Julien-en-Genevois, France. alain.beck@pierre-fabre.com
authors.forename: A
authors.initials: A
authors.lastname: Beck
authors.forename: L
authors.initials: L
authors.lastname: Goetsch
authors.forename: T
authors.initials: T
authors.lastname: Champion
authors.forename: M C
authors.initials: MC
authors.lastname: Bussat
authors.forename: J P
authors.initials: JP
authors.lastname: Aubry
authors.forename: C
authors.initials: C
authors.lastname: Klinguer-Hamour
authors.forename: J F
authors.initials: JF
authors.lastname: Haeuw
authors.forename: J Y
authors.initials: JY
authors.lastname: Bonnefoy
authors.forename: N
authors.initials: N
authors.lastname: Corvaïa
mesh_terms: D000818:Animals; D019496:Cancer Vaccines / Q000737:chemistry / Q000276:immunology* / Q000627:therapeutic use; D002851:Chromatography, High Pressure Liquid; D008545:Melanoma / Q000276:immunology / Q000628:therapy*; D051379:Mice; D008822:Mice, Transgenic; D008958:Models, Molecular; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
chemical_list: D019496:Cancer Vaccines